查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676913

WHIM 症候群市場治療方法、給藥方式、治療用途和最終用戶分類 - 2025-2030 年全球預測

WHIM Syndrome Market by Treatment, Mode of Administration, Therapeutic Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

WHIM 症候群市場預計在 2024 年達到 4.5977 億美元，2025 年達到 4.8575 億美元，到 2030 年達到 6.4777 億美元，複合年成長率為 5.87%。

主要市場統計數據
基準年 2024 年 4.5977億美元
預計 2025 年 4.8575億美元
預測年份 2030 6.4777億美元
複合年成長率（%） 5.87%

WHIM 症候群是一種罕見的免疫力缺乏，其特徵是疣、低丙種球蛋白血症、感染疾病和骨髓發育不良，在臨床管理和市場動態方面都面臨著獨特的挑戰。該疾病是由影響 CXCR4 受體的基因突變引起的，長期以來基本上未被認知，但由於其症狀和合併症複雜，引起了相當大的關注。近年來，人們認知的提高推動了研究和治療方法的進步，治療方法發生了顯著變化。

從醫療保健的角度來看，治療 WHIM 症候群不僅需要臨床干預，還需要協調多學科的努力，包括創新的治療方法、改進的患者管理策略以及採用個人化的治療方法。鑑於法規環境的不斷變化和對罕見疾病的投資不斷增加，WHIM 症候群管理市場正逐漸轉向更個人化和有效的解決方案。透過將科學發現與對患者需求的全面了解相結合，相關人員準備重新定義這一充滿挑戰的領域的治療模式。

本執行摘要透過概述 WHIM 症候群的臨床和市場特定的挑戰和機會，深入探討了 WHIM 症候群的複雜性。目標是為決策者提供可行的見解，彌合臨床創新與市場策略之間的差距，最終改善患者的治療效果並提高新興療法的市場佔有率。

改變 WHIM 症候群市場

近年來，在技術創新和不斷發展的醫療政策的推動下，WHIM 症候群的治療和管理方法發生了重大變化。研究開發和藥物開發正在開拓脫離傳統治療模式的新治療方法。診斷工具和基因組分析的改進現在可以讓我們更精確地了解疾病的遺傳背景，為個人化治療方法鋪平了道路。

對臨床試驗和研究合作的投資正在加速標靶治療的發展，並透過真實世界資料和以患者為中心的研究進一步完善這些治療。監管機構正日益適應這些創新，創造一個鼓勵快速核准突破性治療方法的環境。科學進步和支持性法律規範的融合為重塑 WHIM 症候群的治療架構提供了動力，使患者能夠獲得更安全、更有效的治療。

此外，數位健康平台、遠端醫療和先進監測工具的整合改變了醫療專業人員追蹤患者進展的方式。數位創新與臨床專業知識協同效應，正在徹底改變治療方法並創建一個生態系統，透過主動管理和及時干預可以顯著減少疾病的影響。因此，我們正在經歷一場以研究加速、資金籌措充足以及患者需求和治療方法進步日益一致為標誌的變革。

患者照護和治療方式的關鍵細分洞察

對市場模式的全面分析可以揭示寶貴的細分見解，強調治療方法對於滿足 WHIM 症候群患者的多樣化需求的重要性。市場細分於多個維度，包括治療類型、給藥方式、治療用途和最終用戶設定。每個部分都提供了關於如何客製化治療以提高療效和方便患者的重要見解。

在治療方面，市場主要透過三種不同方式進行評估：顆粒細胞增生因子療法、免疫球蛋白替代療法和預防性抗生素治療。這些治療方法已被廣泛研究，以了解它們的相對療效和安全性，治療方法治療方法在減輕疾病的多方面挑戰方面都發揮關鍵作用。同時，給藥方式大致分為注射劑和口服製劑，反映了快速治療效果與患者舒適度之間的平衡。給藥方法的選擇通常會直接影響依從性和患者的整體結果。

此外，仔細觀察治療應用就會發現，治療策略並不是單一的。自體免疫疾病、血液疾病和感染疾病管理的方法有所不同。自體免疫疾病被認為是內分泌和風濕症候群，而血液疾病的治療則著重於白血球減少症和血小板減少症等症狀。此外，按最終用戶分類的市場涵蓋居家醫療機構、醫院和專科診所，全面展示了這些治療方法的使用地點以及每個醫療保健環境的不同需求。這種分解的見解不僅闡明了當前的實踐，而且為未來改善醫療服務指明了方向。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 罕見遺傳疾病的盛行率和認知度不斷提高
      • 全球醫療成本上漲
      • 政府對罕見疾病藥物研發和罕見疾病的措施和資助
    • 限制因素
      • 罕見疾病藥物研發成本上升
    • 機會
      • 正在進行的針對 WHIM 症候群的聯合研究和開發合作活動
      • 個性化基因治療解決方案的開發進展
    • 任務
      • 標靶治療核准過程中的監管挑戰
  • 市場區隔分析
    • 治療類型：免疫球蛋白替代療法因患者依從性和生活品質提高而越來越受到青睞
    • 治療應用：將 WHIM 症候群治療的應用擴展到自體免疫疾病
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. WHIM 症候群市場（依治療）

  • 顆粒細胞增生因子
  • 免疫球蛋白替代療法
  • 預防性抗生素治療

7. WHIM 症候群市場（依給藥方法）

  • 注射劑
  • 口服

8. WHIM 症候群市場（依治療應用）

  • 自體免疫疾病
    • 內分泌失調
    • 風濕症候群
  • 血液系統疾病
    • 白血球減少症
    • 血小板減少性疾病
  • 感染控制

第 9 章 WHIM 症候群市場（依最終用戶）

  • 家庭護理設置
  • 醫院
  • 專科門診

10. 美洲的 WHIM 症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區 WHIM 症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲的 WHIM 症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Aetna Inc.
  • AstraZeneca Plc
  • Beijing Wantai Biolog Pha Ent Co Ltd
  • Bristol-Myers Squibb Co.
  • Dr. Reddy's Laboratories Ltd
  • Eugia Pharma Inc.
  • GlaxoSmithKline Plc（GSK）
  • Horizonscan geneesmiddelen
  • Incyte Corporation
  • Innovate Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Walvax Biotechnology Co., Ltd.
  • X4 Pharmaceuticals, Inc.
Product Code: MRR-3E7318E83171

The WHIM Syndrome Market was valued at USD 459.77 million in 2024 and is projected to grow to USD 485.75 million in 2025, with a CAGR of 5.87%, reaching USD 647.77 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 459.77 million
Estimated Year [2025] USD 485.75 million
Forecast Year [2030] USD 647.77 million
CAGR (%) 5.87%

WHIM Syndrome, a rare immunodeficiency disorder characterized by Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, presents a unique challenge in both clinical management and market dynamics. This condition, which stems from a genetic mutation affecting the CXCR4 receptor, has long been under-recognized yet demands considerable attention due to its complex interplay of symptoms and comorbidities. In recent years, increased awareness has spurred advancements in research and treatment options, setting the stage for transformative changes in therapeutic landscapes.

From a healthcare perspective, addressing WHIM Syndrome is more than a matter of clinical intervention; it involves coordinating multidisciplinary efforts that encompass innovative treatment regimens, improved patient management strategies, and the adoption of tailored therapies. In light of an evolving regulatory environment and growing investment in rare diseases, the market for WHIM Syndrome management is gradually moving toward more personalized and effective solutions. By integrating scientific discoveries with a comprehensive understanding of patient needs, stakeholders are poised to redefine treatment paradigms in this challenging field.

This executive summary delves into the intricacies of WHIM Syndrome by outlining both the clinical and market-specific challenges as well as opportunities. It aims to equip decision-makers with actionable insights that bridge clinical innovations and market strategies, ultimately leading to enhanced patient outcomes and a robust market presence for emerging therapies.

Transformative Shifts in the Therapeutic Landscape

Recent years have witnessed significant transformative shifts in the approach to treating and managing WHIM Syndrome, driven by both technological innovations and evolving healthcare policies. Researchers and pharmaceutical developers are pioneering novel therapeutic methods that break away from traditional treatment models. Enhanced diagnostic tools and genomic profiling are now enabling a more precise understanding of the disease's genetic underpinnings, paving the way for personalized treatment options.

Investments in clinical trials and research collaborations have accelerated the development of targeted therapies, which have been further refined by real-world data and patient-centric studies. Regulatory bodies are increasingly adapting to these innovations, fostering an environment that encourages rapid approval of breakthrough treatments. The convergence of scientific advancement and supportive regulatory frameworks has provided the impetus to reconfigure the structure of care for WHIM Syndrome, ensuring that patients receive more effective therapies with better safety profiles.

Moreover, the integration of digital health platforms, telemedicine, and advanced monitoring tools has transformed how healthcare professionals track patient progress. This synergy between digital innovation and clinical expertise is revolutionizing treatment delivery, creating an ecosystem where proactive management and timely intervention can significantly mitigate the impact of the syndrome. The landscape is thus undergoing an evolution characterized by accelerated research, robust funding, and a growing alignment between patient needs and therapeutic advancements.

Key Segmentation Insights Across Patient Care and Treatment Modalities

A comprehensive analysis of the market landscape reveals valuable segmentation insights that underscore the importance of tailoring therapeutic approaches to address the diverse needs of patients with WHIM Syndrome. The market is segmented on multiple dimensions including the type of treatment, mode of administration, therapeutic applications, and end-user settings. Each segmentation dimension offers critical insights into how care is being customized for effectiveness and patient convenience.

In terms of treatment, the market is primarily evaluated by three distinct modalities: Granulocyte-Colony Stimulating Factor, Immunoglobulin Replacement Therapy, and Prophylactic Antibiotic Treatment. These treatment options have been studied extensively to understand their relative efficacy and safety profiles, with each therapy playing a pivotal role in mitigating the disease's multifaceted challenges. Meanwhile, the mode of administration is largely divided between injectable and oral platforms, reflecting a balance between rapid therapeutic action and patient comfort. The choice of administration method often directly impacts adherence and overall patient outcomes.

Furthermore, a detailed look into therapeutic applications shows that treatment strategies are not monolithic. Approaches are being differentiated across autoimmune conditions, hematological disorders, and infection management. Intricacies within these categories further refine the analysis as autoimmune conditions are explored in the context of endocrine disorders and rheumatological syndromes, while the management of hematological disorders involves a focus on conditions such as leukopenia and thrombocytopenia. Additionally, the market's segmentation by end user spans home care settings, hospitals, and specialty clinics, revealing a comprehensive view of where these treatments are utilized and the varying needs of each care environment. Such segmented insights not only provide clarity on current practices but also chart a course for future enhancements in therapy delivery.

Based on Treatment, market is studied across Granulocyte-Colony Stimulating Factor, Immunoglobulin Replacement Therapy, and Prophylactic Antibiotic Treatment.

Based on Mode of Administration, market is studied across Injectable and Oral.

Based on Therapeutic Application, market is studied across Autoimmune Conditions, Hematological Disorders, and Infection Management. The Autoimmune Conditions is further studied across Endocrine Disorders and Rheumatological Syndromes. The Hematological Disorders is further studied across Leukopenia and Thrombocytopenia.

Based on End User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Key Regional Insights Reflecting Global Trends in Rare Disease Management

The geographic distribution of WHIM Syndrome management reveals distinct regional trends that are pertinent for both market participants and healthcare providers. In the Americas, a robust healthcare infrastructure combined with proactive research initiatives fosters an environment that is conducive to the rapid adoption of innovative treatment regimens. Here, advanced clinical trials and early adoption of novel therapies blend with structured regulatory frameworks to accelerate market growth.

Across Europe, the Middle East, and Africa, there is a notable drive toward harmonizing clinical standards and integrating multinational research collaborations. This region has experienced a steady surge in investment through both public and private funding channels, pushing advancements in both diagnostic methodologies and therapeutic solutions. The emphasis on creating interconnected networks among healthcare institutions reflects a systematic approach to addressing rare diseases like WHIM Syndrome.

In the Asia-Pacific region, the convergence of significant healthcare reforms, economic growth, and heightened awareness about rare medical conditions has spurred market development. Regulatory evolutions, coupled with increased demand for efficient care delivery models, make this region a hotbed for innovative treatment approaches. Collectively, these regional insights highlight how market dynamics are influenced by local healthcare policies, economic conditions, and cultural factors that shape patient care and treatment acceptance rates on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Market Leadership

Insightful analysis of the market reveals a diverse cohort of companies that are at the forefront of innovation in the treatment of WHIM Syndrome. These organizations are pivotal in advancing research and developing groundbreaking therapies that are reshaping the rare disease landscape. Major players range from well-established pharmaceutical giants to innovative biopharmaceutical firms deeply involved in clinical research and development initiatives.

Noteworthy industry leaders include companies such as Aetna Inc. and AstraZeneca Plc, which have demonstrated consistent commitment to improving patient outcomes through robust research programs. Other influential entities such as Beijing Wantai Biolog Pha Ent Co Ltd and Bristol-Myers Squibb Co. have made significant contributions by leveraging their extensive R&D capabilities to create targeted therapeutic interventions. Additionally, firms like Dr. Reddy's Laboratories Ltd and Eugia Pharma Inc. are actively involved in expanding the accessibility and affordability of care through innovative treatment models.

Industry trailblazers like GlaxoSmithKline Plc, Horizonscan geneesmiddelen, Incyte Corporation, and Innovate Biopharmaceuticals, Inc. continue to push the envelope in both diagnostics and treatment efficacy. In parallel, companies including Intercept Pharmaceuticals and Johnson & Johnson strive to align their expansive product portfolios with the evolving needs of patients. Esteemed players such as Merck & Co., Inc, Pfizer Inc., Roche Holding AG, and Sanofi S.A. leverage their market acumen and extensive distribution networks to ensure that breakthrough treatments reach a global audience. In emerging markets, the contributions of Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Walvax Biotechnology Co., Ltd., and X4 Pharmaceuticals, Inc. highlight a balanced mix of innovation and market penetration that reinforces the dynamic nature of this therapeutic landscape.

The report delves into recent significant developments in the WHIM Syndrome Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., AstraZeneca Plc, Beijing Wantai Biolog Pha Ent Co Ltd, Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd, Eugia Pharma Inc., GlaxoSmithKline Plc (GSK), Horizonscan geneesmiddelen, Incyte Corporation, Innovate Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Johnson & Johnson, Merck & Co., Inc, Pfizer Inc., Roche Holding AG, Sanofi S.A., Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Walvax Biotechnology Co., Ltd., and X4 Pharmaceuticals, Inc.. Actionable Recommendations for Strategic Leadership in Rare Disease Markets

For industry leaders navigating the evolving landscape of WHIM Syndrome management, several strategic recommendations emerge from the latest market insights. It is imperative to invest in research partnerships and adapt to innovative treatment models that enhance both clinical outcomes and patient adherence. Embracing digital transformation, for instance, can facilitate not only real-time patient monitoring but also predictive analytics that optimize therapeutic regimens.

Leaders should focus on bolstering collaborative initiatives with academic institutions and clinical research organizations to accelerate the development and validation of next-generation therapies. Integrating data-driven decision-making processes, grounded in comprehensive market intelligence, will support the rapid assessment of treatment efficacy across varied patient segments. As clinical trials expand into diverse geographic regions, fostering cross-border collaborations will be essential for harmonizing standards of care and ensuring regulatory compliance.

Moreover, aligning with healthcare payers and regulatory bodies to create adaptable and patient-centric value propositions is critical. This alignment calls for a deeper understanding of evolving reimbursement models and regional market dynamics, enabling companies to optimize their supply chains and distribution networks for greater market penetration. By focusing on comprehensive patient education programs and leveraging continuous feedback loops, leaders can build robust systems that preemptively address the complexities inherent in managing rare diseases.

The amalgamation of these strategic initiatives promises to not only enhance market competitiveness but also ensure that emerging therapies translate into measurable improvements in patient quality of life. Embracing this multifaceted approach will empower industry executives to drive sustainable growth in a rapidly evolving market environment.

Conclusion: Synthesizing Insights and Shaping Future Direction

In summary, the analysis of WHIM Syndrome reveals an intricate interplay between clinical innovation and market dynamics. The evolution of treatment methodologies, from advanced pharmacotherapies to cutting-edge digital health solutions, has reshaped the understanding of rare diseases and their management. Insights drawn from extensive segmentation, which encompass treatment modalities, modes of administration, therapeutic applications, and various patient care settings, underscore the tailored approaches that are emerging in this niche yet critical therapeutic area.

Global regional insights further augment this narrative by illustrating how healthcare policies, economic growth, and cultural influences converge to impact market trajectories across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. This multi-regional perspective not only highlights the localized nuances in treatment adoption but also stresses the importance of unified efforts in addressing rare diseases on a global stage.

Moreover, the presence of key players-from established pharmaceutical giants to agile biopharmaceutical innovators-reinforces the notion that a competitive and dynamic market is one in which continuous innovation is not just encouraged but necessary for survival. Their forward-thinking initiatives and commitment to robust research and development serve as a testament to the transformative shifts in the therapeutic landscape. Ultimately, these insights come together to form a coherent picture of a market poised for growth, driven by both scientific rigor and strategic foresight.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence and awareness of rare genetic disorders
      • 5.1.1.2. Growing global healthcare expenditure
      • 5.1.1.3. Government initiatives and funding support for orphan drug development and rare diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High research and development costs in rare disease drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing collaborative activities for collaborative research and development on WHIM syndrome
      • 5.1.3.2. Advancements in the development of personalized gene therapy solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory challenges in approvals processes for targeted therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing preference for immunoglobulin replacement therapy for improved patient compliance and quality of life
    • 5.2.2. Therapeutic Application: Expanding application of WHIM syndrome treatments in autoimmune conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. WHIM Syndrome Market, by Treatment

  • 6.1. Introduction
  • 6.2. Granulocyte-Colony Stimulating Factor
  • 6.3. Immunoglobulin Replacement Therapy
  • 6.4. Prophylactic Antibiotic Treatment

7. WHIM Syndrome Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. WHIM Syndrome Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Autoimmune Conditions
    • 8.2.1. Endocrine Disorders
    • 8.2.2. Rheumatological Syndromes
  • 8.3. Hematological Disorders
    • 8.3.1. Leukopenia
    • 8.3.2. Thrombocytopenia
  • 8.4. Infection Management

9. WHIM Syndrome Market, by End User

  • 9.1. Introduction
  • 9.2. Home Care Settings
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas WHIM Syndrome Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific WHIM Syndrome Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa WHIM Syndrome Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. X4 Pharmaceuticals leverages USD 125 million capital enhances to advance mavorixafor for WHIM syndrome
    • 13.3.2. FDA approved XOLREMDI (mavorixafor), a CXCR4 antagonist developed by X4 Pharmaceuticals
    • 13.3.3. FDA approves first drug for WHIM syndrome, a rare disorder
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetna Inc.
  • 2. AstraZeneca Plc
  • 3. Beijing Wantai Biolog Pha Ent Co Ltd
  • 4. Bristol-Myers Squibb Co.
  • 5. Dr. Reddy's Laboratories Ltd
  • 6. Eugia Pharma Inc.
  • 7. GlaxoSmithKline Plc (GSK)
  • 8. Horizonscan geneesmiddelen
  • 9. Incyte Corporation
  • 10. Innovate Biopharmaceuticals, Inc.
  • 11. Intercept Pharmaceuticals
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi S.A.
  • 17. Serum Institute of India Pvt. Ltd.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Walvax Biotechnology Co., Ltd.
  • 20. X4 Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. WHIM SYNDROME MARKET MULTI-CURRENCY
  • FIGURE 2. WHIM SYNDROME MARKET MULTI-LANGUAGE
  • FIGURE 3. WHIM SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 4. WHIM SYNDROME MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL WHIM SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL WHIM SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL WHIM SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL WHIM SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES WHIM SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES WHIM SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. WHIM SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. WHIM SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. WHIM SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL WHIM SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL WHIM SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. WHIM SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL WHIM SYNDROME MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL WHIM SYNDROME MARKET SIZE, BY IMMUNOGLOBULIN REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL WHIM SYNDROME MARKET SIZE, BY PROPHYLACTIC ANTIBIOTIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL WHIM SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL WHIM SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL WHIM SYNDROME MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL WHIM SYNDROME MARKET SIZE, BY RHEUMATOLOGICAL SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL WHIM SYNDROME MARKET SIZE, BY LEUKOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL WHIM SYNDROME MARKET SIZE, BY THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL WHIM SYNDROME MARKET SIZE, BY INFECTION MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL WHIM SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL WHIM SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL WHIM SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES WHIM SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA WHIM SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY AUTOIMMUNE CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM WHIM SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. WHIM SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 279. WHIM SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024